Marginally excised parotid pleomorphic salivary adenomas: risk factors for recurrence and management. A 12.5-year mean follow-up study of histologically marginal excisions

被引:62
作者
Ghosh, S
Panarese, A
Bull, PD
Lee, JA
机构
[1] Rotherham Gen Hosp, Dept Histopathol, Rotherham S60 2UD, S Yorkshire, England
[2] Royal Hallamshire Hosp, Dept Otolaryngol, Sheffield S10 2JF, S Yorkshire, England
来源
CLINICAL OTOLARYNGOLOGY | 2003年 / 28卷 / 03期
关键词
parotid gland; parotid pleomorphic adenoma; pleomorphic salivary adenoma; margins; mixed tumour; recurrence;
D O I
10.1046/j.1365-2273.2003.00704.x
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The aim of the study was to identify recurrence risk factors in surgically excised parotid pleomorphic salivary adenomas. We reviewed the case histories and histological findings for all cases of marginal or inadequate excision of pleomorphic salivary adenomas at the Royal Hallamshire Hospital, Sheffield, UK, between 1980 and 1995. A total of 83 cases with complete records were identified, with a mean follow-up period of 12.5 years. The histological slides were reviewed in each case. The overall recurrence rate was 6.0%. Where tumour was present at the margin, recurrence occurred in 17.6% of cases. However, cases conventionally regarded as marginally excised and likely to recur (tissue margin<1 mm) showed recurrence in only 1.8% of cases. Intraoperative capsular rupture, microscopic capsular invasion by tumour and several other surgical factors were not predictive of recurrence. Adequate excision of pleomorphic salivary adenomas, in the sense of minimal recurrence risk, does not require more than a fraction of a millimetre of surrounding tissue. Only pleomorphic salivary adenomas with tumour actually at the excision margin require prolonged follow-up or consideration of radiotherapy. Provided that the tumour can be removed intact, the surgical approach for pleomorphic salivary adenomas should be guided by the need to preserve vital structures rather than by an attempt to remove a cuff of normal tissue with the tumour.
引用
收藏
页码:262 / 266
页数:5
相关论文
共 12 条
[1]   RADIOTHERAPY FOR PLEOMORPHIC ADENOMA OF THE PAROTID-GLAND [J].
BARTON, J ;
SLEVIN, NJ ;
GLEAVE, EN .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (05) :925-928
[2]  
Batsakis JG, 1979, TUMORS HEAD NECK CLI, P1
[3]  
CONLEY J, 1979, ARCH OTOLARYNGOL, V105, P247
[4]  
DONOVAN DT, 1984, LARYNGOSCOPE, V94, P324
[5]  
FRAZELL EL, 1954, CANCER, V7, P637, DOI 10.1002/1097-0142(195407)7:4<637::AID-CNCR2820070403>3.0.CO
[6]  
2-#
[7]  
KROLLS SO, 1972, CANCER, V30, P276, DOI 10.1002/1097-0142(197207)30:1<276::AID-CNCR2820300138>3.0.CO
[8]  
2-V
[9]  
Leverstein H, 1997, BRIT J SURG, V84, P399
[10]   Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas [J].
McGurk, M ;
Renehan, A ;
Gleave, EN ;
Hancock, BD .
BRITISH JOURNAL OF SURGERY, 1996, 83 (12) :1747-1749